Enhanced with market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, The Business Research Company’s 2026 market reports deliver more actionable and strategically valuable research.
Primary Biliary Cholangitis Therapeutics Market Revenue Growth Supported By A CAGR Of 1.85% Through 2030
The market for primary biliary cholangitis therapeutics has experienced notable expansion in recent times. Valued at $1.01 billion in 2025, it is projected to rise to $1.14 billion by 2026, achieving a compound annual growth rate (CAGR) of 12.9%. Factors driving growth during the historical period include the scarcity of treatment alternatives for PBC, a rising incidence of autoimmune liver conditions, enhanced public awareness initiatives focused on liver diseases, dependence on ursodeoxycholic acid as a standalone therapy, and the broadening of hospital facilities dedicated to liver disease management.
The market for primary biliary cholangitis therapeutics is projected to experience rapid expansion over the coming years. By 2030, it is anticipated to reach $1.85 billion, reflecting a compound annual growth rate (CAGR) of 12.9%. This forecast period growth is driven by factors such as the progression of obeticholic acid and combination therapies, a rise in investigational drugs and pipeline candidates, increased utilization of receptor agonists and modulators, heightened patient awareness and early diagnosis efforts, and the broadening of online and retail pharmacy distribution networks. Key trends shaping the forecast period include the growing adoption of ursodeoxycholic acid and obeticholic acid treatments, expansion of combination therapies and pipeline medications, a stronger emphasis on early detection and disease management, wider distribution through hospital and retail pharmacy channels, and increased awareness of autoimmune liver diseases coupled with patient education initiatives.
Download A Free Sample Report For Comprehensive Market Insights:
Primary Biliary Cholangitis Therapeutics Market Expansion Supported By Key Demand Factors
The primary biliary cholangitis therapeutics market is anticipated to expand due to the rising incidence of liver diseases. These diseases encompass a range of disorders that disrupt normal liver function, commonly resulting in inflammation, scarring, or liver failure. The growing frequency of such conditions is linked to higher alcohol consumption, as excessive drinking damages liver cells, triggering inflammation and chronic liver issues. Treatments for primary biliary cholangitis address bile duct inflammation, slow disease advancement, and maintain liver function, thereby enhancing patient outcomes by alleviating symptoms, boosting quality of life, and postponing the requirement for a liver transplant. As an example, in September 2025, the Centers for Disease Control and Prevention (CDC), a federal public health agency in the US, reported that chronic liver disease and cirrhosis led to 52,222 fatalities in the United States during 2023, positioning it as the ninth leading cause of death. Consequently, the increasing burden of liver diseases is fueling growth in the primary biliary cholangitis therapeutics market.
Primary Biliary Cholangitis Therapeutics Market Segmentation And Category Breakdown
The primary biliary cholangitis therapeutics market covered in this report is segmented –
1) By Drug: Ursodeoxycholic Acid, Obeticholic Acid, Other Drugs
2) By Mechanism Of Action (MOA): Receptor Agonist, Receptor Modulator, Enzyme Activator, Enzyme Inhibitor, Other Mechanisms Of Action
3) By Distribution Channel: Hospital Pharmacies, Drug Store And Retail Pharmacies, Online Pharmacies
4) By Use: Human, Veterinary
Subsegments:
1) By Ursodeoxycholic Acid: Branded Ursodeoxycholic Acid, Generic Ursodeoxycholic Acid, Combination Therapies With Ursodeoxycholic Acid
2) By Obeticholic Acid: Monotherapy, Combination Therapy, Branded Obeticholic Acid
3) By Other Drugs: Fibrates, Budesonide, Immunosuppressants, Investigational Drugs Or Pipeline Candidates
Primary Biliary Cholangitis Therapeutics Market Growth Trends Influencing Competitive Dynamics
Key industry players in the primary biliary cholangitis therapeutics market are concentrating on the development of innovative therapies and securing regulatory approvals, including peroxisome proliferator-activated receptor agonists, aimed at enhancing bile acid metabolism and decelerating the advancement of the disease in patients. These peroxisome proliferator-activated receptor (PPAR) agonists function by activating PPAR proteins, which control genes related to metabolic processes, inflammatory responses, and energy homeostasis. As an example, in August 2024, Gilead Sciences Inc., a pharmaceutical firm based in the United States, was granted accelerated approval by the U.S. Food and Drug Administration (FDA) for Livdelzi (seladelpar) to manage primary biliary cholangitis (PBC) among adults who either show an insufficient response to ursodeoxycholic acid (UDCA) or are unable to tolerate it. This medication, administered orally, acts as a selective PPARd agonist, stimulating the PPARd receptor to modulate genes associated with decreasing liver inflammation, optimizing bile acid metabolism, and slowing the progression of primary biliary cholangitis (PBC).
Primary Biliary Cholangitis Therapeutics Market Competitive Analysis Of Major Industry Participants
Major companies operating in the primary biliary cholangitis therapeutics market are Novartis AG, Gilead Sciences Inc., Ipsen Pharma, Intercept Pharmaceuticals, Enanta Pharmaceuticals, Mirum Pharmaceuticals, Calliditas Therapeutics AB, Dr. Falk Pharma GmbH, NGM Biopharmaceuticals Inc., COUR Pharmaceuticals, HighTide Therapeutics Inc., Pliant Therapeutics Inc., Tiziana Life Sciences, Phenex Pharmaceuticals, Synlogic Therapeutics
Access The Complete Primary Biliary Cholangitis Therapeutics Market Report:
Primary Biliary Cholangitis Therapeutics Market Geographic Landscape: Which Region Dominates Industry Growth?
North America was the largest region in the primary biliary cholangitis therapeutics market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the primary biliary cholangitis therapeutics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/?utm_source=BlogsPR&utm_medium=Paid&utm_campaign=home_page_test
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model